Cabaletta Bio Inc. is currently recognized as a penny stock with promising growth prospects.
The company is in the process of preparing for the commercial launch of its product, Rese-Cel.
Rese-Cel is specifically designed to target autoimmune diseases, which represents a significant and expanding market.